Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that it has received US Food and Drug Administration (FDA) approval for Gazyva (obinutuzumab) to treat adults with primary membranous nephropathy (pMN) at risk of disease progression, making it the first and only approved treatment for the condition.
The approval is based on Phase III MAJESTY trial results, which showed that 36.1% of patients receiving Gazyva achieved complete remission of proteinuria after two years, compared with 5.7% for tacrolimus. Overall remission rates were 50% and 12.9%, respectively, with no new safety signals identified.
Primary membranous nephropathy is a rare, chronic autoimmune disease that can cause irreversible kidney damage and progress to kidney failure.
This approval marks Gazyva's third FDA authorisation in immune-mediated kidney diseases, following previous approvals for idiopathic nephrotic syndrome and lupus nephritis. The FDA is also reviewing Gazyva for systemic lupus erythematosus, with a decision expected by December 2026, while a European regulatory decision is anticipated following a positive recommendation from the CHMP.
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology